Kedrion Biopharma Inc. has expanded the distribution network for Ryplazim, a plasma-derived human plasminogen indicated for treating patients with plasminogen deficiency type 1 (PLGD-1). This expansion ensures timely access to this vital medication for patients across the US. PLGD-1 is a serious condition causing abnormal fibrin-rich lesions on mucosal surfaces, potentially leading to severe consequences like vision and hearing loss, airway obstruction, and infertility. Ryplazim, the only FDA approved therapy for PLGD-1 patients, offers an important treatment option.
The recent FDA approval of the technology transfer and manufacturing capacity expansion of Ryplazim has enabled Kedrion to broaden its limited distribution network due to the increase of supply. This crucial step means more patients can have access to this treatment. The expanded network now includes a new distribution partner and two new specialty pharmacies.
CuraScript SD a provider of comprehensive distribution solutions, joins existing partners FFF Enterprises and The Alliance Pharmacy in distributing Ryplazim to patients with PLGD-1.
CVS Health and Soleo Health have been added to the list of specialty pharmacies carrying Ryplazim, increasing access points for patients. These pharmacies join Nufactor, enhancing the network to ensure wider availability.
This collaborative effort underscores Kedrion's commitment to improving patient care and broadening access to essential therapies.
"The FDA's approval of the tech transfer and capacity expansion enables us to manufacture greater volumes of Ryplazim. We are focused on educating healthcare providers on identifying and diagnosing PLGD-1 patients. Once diagnosed, a strong infrastructure is essential to ensure timely product delivery and an improvement in care for patients.
Our goal is to ensure that every patient has reliable access to therapy they may need for the rest of their life. This distribution network is a significant step toward making that goal a reality." - said Bob Rossilli, CCO, Global Business and US General Manager.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!